Salvage Treatment With Lenalidomide and Dexamethaosne (LEN-DEX) in Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL)
This is a prospective, multicenter phase II trial designed to evaluate the safety and activity of the combination of Lenalidomide (Len) and Dexamethasone (Dex) in patients with relapsed/refractory mantle cell lymphoma (MCL).
MANTLE CELL LYMPHOMA
DRUG: Lenalidomide and Dexametasone
To explore the antitumor activity of the association of Len-Dex in term of overall (OR) and complete response (CR) in patients with relapsed/refractory MCL, 3 years
To explore the safety profile;, 2 years|To explore the modification of tumoral neo-angiogenic biomarkers and the relationship with response to Len-Dex therapy;, 2 years|To evaluate the clinical efficacy of Len-Dex in terms of response duration (RD) and overall survival (OS)., 2 years
This is a prospective, multicenter phase II trial designed to evaluate the safety and activity of the combination of Lenalidomide (Len) and Dexamethasone (Dex) in patients with relapsed/refractory mantle cell lymphoma (MCL).